Therapeutic Asset Ratings
567 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urinary Bladder Cancer
Fred Hutchinson Cancer Center
P2
BB
(66)
FILGRASTIM
Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
P2
BB
(66)
METHOTREXATE
Congenital Amegakaryocytic Thrombocytopenia
Fred Hutchinson Cancer Center
P2
BB
(66)
METHOTREXATE
Diamond-Blackfan Anemia
Fred Hutchinson Cancer Center
P2
BB
(66)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
P2/3
BB
(66)
Cytosin-Arabinosid
Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
P3
BB
(65)
METHOTREXATE
Acute Biphenotypic Leukemia
Fred Hutchinson Cancer Center
P3
BB
(65)
Pembrolizumab
Renal Pelvis Urothelial Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(65)
Pembrolizumab
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(65)
Pembrolizumab
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P2
BB
(65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P2
BB
(65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Stage IV Bladder Cancer AJCC v8
Fred Hutchinson Cancer Center
P2
BB
(65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Malignant Renal Pelvis Neoplasm
Fred Hutchinson Cancer Center
P2
BB
(65)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Ureter Cancer
Fred Hutchinson Cancer Center
P2
BB
(65)
Fludarabine
CD4+/CD56+ Hematodermic Neoplasm
Fred Hutchinson Cancer Center
P2
BB
(65)
Fludarabine
Mast Cell Leukemia
Fred Hutchinson Cancer Center
P2
BB
(65)
Jcar017 (Lisocabtagene Maraleucel)
Primary Mediastinal Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
P2
BB
(65)
TACROLIMUS
Hematopoietic And Lymphoid Cell Neoplasm
Fred Hutchinson Cancer Center
P2
BB
(65)
Fludarabine
Plasma Cell Myeloma
Fred Hutchinson Cancer Center
P4
BB
(64)
Cediranib
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fred Hutchinson Cancer Center
P3
BB
(64)
CYCLOSPORIN A
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
P3
BB
(64)
Decitabine
Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
P3
BB
(64)
Nivolumab
Nonpapillary Renal Cell Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(64)
Nivolumab
Metastatic Cancer
Fred Hutchinson Cancer Center
P3
BB
(64)
Showing 101 to 125 of 567 assets
Previous
Page 5 of 23
Next